{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T12:06:59Z","timestamp":1779883619794,"version":"3.53.1"},"reference-count":34,"publisher":"SAGE Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JHD"],"published-print":{"date-parts":[[2024,9,10]]},"abstract":"<jats:p>Background: Huntington\u2019s disease (HD) exerts significant impacts on individuals and families worldwide. Nevertheless, data on its economic burden in Brazil are scarce, revealing a critical gap in understanding the associated healthcare costs. Objective: This study was conducted at a tertiary neurology outpatient clinic in Brazil with the aim of assessing annual healthcare service utilization and associated costs for HD patients. Methods: We conducted a cross-sectional observational study involving 34 HD patients. A structured questionnaire was applied to collect data on direct medical costs (outpatient services, medications), non-medical direct costs (complementary therapies, mobility aids, home adaptations), and indirect costs (lost productivity, caregiver costs, government benefits) over one year. Results: Significant economic impacts were observed, with average annual direct medical costs of $4686.82 per HD patient. Non-medical direct and indirect costs increased the financial burden, highlighting extensive resource utilization beyond healthcare services. Thirty-three out of 34 HD patients were unemployed or retired, and 16 relied on government benefits, reflecting broader socioeconomic implications. Despite the dataset\u2019s limitations, it provides crucial insights into the economic impact of HD on patients and the Brazilian public health system. Conclusions: The findings underscore the urgent need for a more comprehensive evaluation of the costs to inform governmental policies related to HD. Future research is needed to expand the data pool and develop a nuanced understanding of the economic burdens of HD to help formulate effective healthcare strategies for patients.<\/jats:p>","DOI":"10.3233\/jhd-240025","type":"journal-article","created":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T11:55:15Z","timestamp":1723809315000},"page":"349-356","source":"Crossref","is-referenced-by-count":1,"title":["Economic Burden of Huntington\u2019s Disease: Analysis from a Brazilian Tertiary Care Perspective"],"prefix":"10.1177","volume":"13","author":[{"given":"Andressa","family":"da Silva van der Laan","sequence":"first","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo, Departmentof Neurology and Neurosurgery, R. Pedro de Toledo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanderci","family":"Borges","sequence":"additional","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo, Departmentof Neurology and Neurosurgery, R. Pedro de Toledo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta Arb","family":"Saba","sequence":"additional","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo, Departmentof Neurology and Neurosurgery, R. Pedro de Toledo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrique Ballalai","family":"Ferraz","sequence":"additional","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo, Departmentof Neurology and Neurosurgery, R. Pedro de Toledo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JHD-240025_ref1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","article-title":"Huntington\u2019s disease: from molecular pathogenesis to clinical treatment","volume":"10","author":"Ross","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.3233\/JHD-240025_ref2","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1750-1172-5-40","article-title":"Huntington\u2019s disease: a clinical review","volume":"5","author":"Roos","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"10.3233\/JHD-240025_ref3","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1002\/mds.23762","article-title":"A tale of two factors: what determines the rate of progression in Huntington\u2019s disease? A longitudinal MRI study","volume":"26","author":"Rosas","year":"2011","journal-title":"Mov Disord"},{"key":"10.3233\/JHD-240025_ref4","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","article-title":"Huntington\u2019s disease","volume":"369","author":"Walker","year":"2007","journal-title":"Lancet"},{"key":"10.3233\/JHD-240025_ref5","first-page":"694","article-title":"The burden of Huntington\u2019s disease: A prospective longitudinal study of patient\/caregiver pairs","volume":"19","author":"Youssov","year":"2013","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JHD-240025_ref6","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1172\/JCI25424","article-title":"Antisense oligonucleotide therapy for neurodegenerative disease","volume":"116","author":"Smith","year":"2006","journal-title":"J Clin Invest"},{"key":"10.3233\/JHD-240025_ref7","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000443738","article-title":"The prevalence of Huntington\u2019s disease","volume":"46","author":"Rawlins","year":"2016","journal-title":"Neuroepidemiology"},{"key":"10.3233\/JHD-240025_ref8","unstructured":"Huntington AB . Fam\u00edlias cadastradas na ABH - Associa\u00e7\u00e3o Brasil Huntington. 2021. Available from: https:\/\/www.abh.org.br\/."},{"key":"10.3233\/JHD-240025_ref9","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1590\/1678-4685-gmb-2018-0032","article-title":"Minimal prevalence of Huntington\u2019s disease in the South of Brazil and instability of the expanded CAG tract during intergenerational transmissions","volume":"42","author":"de Castilhos","year":"2019","journal-title":"Genet Mol Biol"},{"key":"10.3233\/JHD-240025_ref10","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1159\/000434630","article-title":"A study of a geographical cluster of Huntington\u2019s disease in a Brazilian town of Zona da Mata, Minas Gerais state","volume":"74","author":"Agostinho","year":"2015","journal-title":"Eur Neurol"},{"issue":"Suppl 1","key":"10.3233\/JHD-240025_ref11","doi-asserted-by":"crossref","first-page":"A22","DOI":"10.1136\/jnnp.2010.22638.5","article-title":"Prevalence of Huntington\u2019s disease in Feira Grande, a small city in northeastern Brazil","volume":"81","author":"Alencar","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JHD-240025_ref12","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.3111\/13696998.2013.818545","article-title":"The direct medical costs of Huntington\u2019s disease by stage: a retrospective commercial and Medicaid claims data analysis","volume":"16","author":"Divino","year":"2013","journal-title":"J Med Econ"},{"key":"10.3233\/JHD-240025_ref13","first-page":"81","article-title":"Utilisation of healthcare and associated services in Huntington\u2019s disease: a data mining study","volume":"1","author":"Busse","year":"2011","journal-title":"J Huntingtons Dis"},{"key":"10.3233\/JHD-240025_ref14","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1474-4422(09)70178-4","article-title":"Beyond the brain: widespread pathology in Huntington\u2019s disease","volume":"8","author":"van der Burg","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.3233\/JHD-240025_ref15","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1111\/ene.13107","article-title":"The societal cost of Huntington\u2019s disease: are we underestimating the burden?","volume":"23","author":"Jones","year":"2016","journal-title":"Eur J Neurol"},{"key":"10.3233\/JHD-240025_ref16","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1177\/0020731417732543","article-title":"The National Health Services of Brazil and Northern Europe: universality, equity, and integrality\u2014 time has come for the latter","volume":"47","author":"Gurgel","year":"2017","journal-title":"Int J Health Serv"},{"key":"10.3233\/JHD-240025_ref17","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.2147\/CIA.S151919","article-title":"Average annual cost of Parkinson\u2019s disease in S\u00e3o Paulo, Brazil, with a focus on disease-related motor symptoms","volume":"12","author":"Bovolenta","year":"2017","journal-title":"Clin Interv Aging"},{"key":"10.3233\/JHD-240025_ref18","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1186\/s12913-019-4806-6","article-title":"Economic burden of Huntington\u2019s disease in Peru","volume":"19","author":"Silva-Paredes","year":"2019","journal-title":"BMC Health Serv Res"},{"issue":"Suppl 3","key":"10.3233\/JHD-240025_ref19","first-page":"iii 60","article-title":"The use of health economic information by reimbursement authorities","volume":"42","author":"Drummond","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"10.3233\/JHD-240025_ref20","first-page":"167","article-title":"Cost of illness studies: what is good about them?","volume":"19","author":"Rice","year":"2000","journal-title":"J Health Econ"},{"key":"10.3233\/JHD-240025_ref21","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0167-6296(94)00044-5","article-title":"The friction cost method for measuring indirect costs of disease","volume":"14","author":"Koopmanschap","year":"1995","journal-title":"J Health Econ"},{"key":"10.3233\/JHD-240025_ref22","first-page":"1989","volume-title":"Generalized Linear Models","author":"McCullagh"},{"key":"10.3233\/JHD-240025_ref23","first-page":"179","article-title":"Healthcare utilization and cost burden of Huntington\u2019s disease among Medicare beneficiaries in the United States","volume":"25","author":"Exuzides","year":"2022","journal-title":"J Med Econ"},{"key":"10.3233\/JHD-240025_ref24","first-page":"1064","article-title":"Healthcare utilization and direct medical costs of Huntington\u2019s disease among Medicaid beneficiaries in the United States","volume":"24","author":"Patel","year":"2021","journal-title":"J Med Econ"},{"key":"10.3233\/JHD-240025_ref25","first-page":"1591","article-title":"Healthcare utilization, costs, and epidemiology of Huntington\u2019s disease in Israel","volume":"269","author":"Barer","year":"2022","journal-title":"J Neurol"},{"key":"10.3233\/JHD-240025_ref26","first-page":"320","article-title":"Economic burden of Huntington\u2019s disease in China: results from a nationwide cross-sectional study","volume":"56","author":"Chen","year":"2022","journal-title":"Neuroepidemiology"},{"key":"10.3233\/JHD-240025_ref27","first-page":"265","article-title":"A cost model for neurological diseases in Puerto Rico: Parkinson\u2019s disease, Alzheimer\u2019s disease and Huntington\u2019s disease","volume":"9","author":"Ortiz","year":"2020","journal-title":"J Huntingtons Dis"},{"key":"10.3233\/JHD-240025_ref28","first-page":"1337","article-title":"Economic burden of Huntington disease in Europe and the USA: results from the Huntington\u2019s Disease Burden of Illness study","volume":"29","author":"Rodr\u00edguez-Santana","year":"2022","journal-title":"Eur J Neurol"},{"key":"10.3233\/JHD-240025_ref29","first-page":"1046","article-title":"Epidemiology and economic burden of Huntington\u2019s disease: a Canadian provincial public health system perspective","volume":"24","author":"Shaw","year":"2021","journal-title":"J Med Econ"},{"key":"10.3233\/JHD-240025_ref30","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1111\/ene.15385","article-title":"Natural history and burden of Huntington\u2019s disease in the UK: a population-based cohort study","volume":"29","author":"Furby","year":"2022","journal-title":"Eur J Neurol"},{"key":"10.3233\/JHD-240025_ref31","unstructured":"Lundbeck (Deerfield). Xenazine\u2122 (tetrabenazine) [prescribing information]. Deerfield: Lundbeck, 2015."},{"key":"10.3233\/JHD-240025_ref33","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1016\/S0140-6736(18)30994-2","article-title":"Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016","volume":"391","author":"GBD 2016 Healthcare Access and Quality Collaborators","year":"2018","journal-title":"Lancet"},{"key":"10.3233\/JHD-240025_ref34","unstructured":"International Labour Organization (ILO). Global Wage Report 2020-21: Wages and minimum wages in the time of COVID-19. Geneva: ILO. https:\/\/www.ilo.org\/global\/publications\/books\/WCMS_762534\/lang\u2013en\/index.htm (2022)."},{"key":"10.3233\/JHD-240025_ref35","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1186\/s12916-023-02957-w","article-title":"Financial hardship associated with catastrophic out-of-pocket spending tied to primary care services in low- and lower-middle-income countries: findings from a modeling study","volume":"21","author":"Bolongaita","year":"2023","journal-title":"BMC Med"}],"container-title":["Journal of Huntington's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JHD-240025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:56:27Z","timestamp":1777452987000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JHD-240025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,10]]},"references-count":34,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.3233\/jhd-240025","relation":{},"ISSN":["1879-6397","1879-6400"],"issn-type":[{"value":"1879-6397","type":"print"},{"value":"1879-6400","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,10]]}}}